83 FR 16110 - Use of Public Human Genetic Variant Databases To Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics; Guidance for Stakeholders and Food and Drug Administration Staff; Availability

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 83, Issue 72 (April 13, 2018)

Page Range		16110-16112
FR Document		2018-07686

The Food and Drug Administration (FDA or Agency) is announcing the availability of the final guidance entitled ``Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics; Guidance for Stakeholders and Food and Drug Administration Staff.'' This guidance document describes how publicly accessible databases of human genetic variants can serve as sources of valid scientific evidence to support the clinical validity of genotype-phenotype relationships in FDA's regulatory review of genetic and genomic-based tests. This guidance further outlines the process by which administrators of genetic variant databases could voluntarily apply to FDA for recognition, and how FDA would review such applications and periodically reevaluate recognized databases.

Federal Register, Volume 83 Issue 72 (Friday, April 13, 2018)

[Federal Register Volume 83, Number 72 (Friday, April 13, 2018)]
[Notices]
[Pages 16110-16112]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-07686]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-1233]


Use of Public Human Genetic Variant Databases To Support Clinical 
Validity for Genetic and Genomic-Based In Vitro Diagnostics; Guidance 
for Stakeholders and Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of the final guidance entitled ``Use of Public Human 
Genetic Variant Databases to Support Clinical Validity for Genetic and 
Genomic-Based In Vitro Diagnostics; Guidance for Stakeholders and Food 
and Drug Administration Staff.'' This guidance document describes how 
publicly accessible databases of human genetic variants can serve as 
sources of valid scientific evidence to support the clinical validity 
of genotype-phenotype relationships in FDA's regulatory review of 
genetic and genomic-based tests. This guidance further outlines the 
process by which administrators of genetic variant databases could 
voluntarily apply to FDA for recognition, and how FDA would review such 
applications and periodically reevaluate recognized databases.

DATES: The announcement of the guidance is published in the Federal 
Register on April 13, 2018.

ADDRESSES: You may submit either electronic or written comments on 
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-D-1233 for ``Use of Public Human Genetic Variant Databases to 
Support Clinical Validity for Genetic and Genomic-Based In Vitro 
Diagnostics; Guidance for Stakeholders and Food and Drug Administration 
Staff.'' Received comments will be placed in the docket and, except for 
those submitted as ``Confidential Submissions,'' publicly viewable at 
https://www.regulations.gov or at the Dockets Management Staff office 
between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

[[Page 16111]]

    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    An electronic copy of the guidance document is available for 
download from the internet. See the SUPPLEMENTARY INFORMATION section 
for information on electronic access to the guidance. Submit written 
requests for a single hard copy of the guidance document entitled ``Use 
of Public Human Genetic Variant Databases to Support Clinical Validity 
for Genetic and Genomic-Based In Vitro Diagnostics; Guidance for 
Stakeholders and Food and Drug Administration Staff '' to the Office of 
the Center Director, Guidance and Policy Development, Center for 
Devices and Radiological Health, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002, 
or the Office of Communication, Outreach, and Development, Center for 
Biologics Evaluation and Research, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002. 
Send one self-addressed adhesive label to assist that office in 
processing your request.

FOR FURTHER INFORMATION CONTACT: Laura Koontz, Center for Devices and 
Radiological Health, Food and Drug Administration, 10903 New Hampshire 
Ave., Bldg. 66, Rm. 4553, Silver Spring, MD 20993-0002, 301-796-7561, 
[email protected]; or Stephen Ripley, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.

SUPPLEMENTARY INFORMATION: 

I. Background

    This guidance document describes one part of FDA's effort to create 
a flexible regulatory approach to the oversight of genetic and genomic-
based tests. FDA held three workshops on this issue: ``Use of Databases 
for Establishing the Clinical Relevance of Human Genetic Variants'' on 
November 13, 2015, ``Patient and Medical Professional Perspectives on 
the Return of Genetic Test Results'' on March 2, 2016, and ``Adapting 
Regulatory Oversight of Next Generation Sequencing-Based Tests'' on 
September 23, 2016. The goal of this effort is to help ensure patients 
receive accurate and meaningful results, while promoting innovation in 
test development. This guidance document describes how publicly 
accessible databases of human genetic variants can serve as sources of 
valid scientific evidence to support the clinical validity of genotype-
phenotype relationships in FDA's regulatory review of genetic and 
genomic-based tests. FDA is also issuing a guidance entitled 
``Considerations for Design, Development, and Analytical Validation of 
Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) 
Intended to Aid in the Diagnosis of Suspected Germline Diseases--
Guidance for Stakeholders and Food and Drug Administration Staff,'' 
which is being released concurrently elsewhere in this issue of the 
Federal Register.
    NGS can enable rapid, broad, and deep sequencing of a portion of a 
gene, entire exome(s), or a whole genome and may be used clinically for 
a variety of diagnostic purposes, including risk prediction, diagnosis, 
and treatment selection for a disease or condition. The rapid adoption 
of NGS-based tests in both research and clinical practice is leading to 
identification of an increasing number of genetic variants (e.g., 
pathogenic, benign, and of unknown significance), including rare 
variants that may be unique to a single individual or family. This 
guidance document describes FDA's considerations in determining whether 
a genetic variant database is a source of valid scientific evidence 
that could support the clinical validity of genetic and genomic based 
tests. This guidance further outlines the process by which 
administrators of genetic variant databases could voluntarily apply to 
FDA for recognition, and how FDA would review such applications and 
periodically reevaluate recognized databases. A draft guidance was 
announced in the Federal Register on July 8, 2016 (81 FR 44611) and 
made available for public comment. The comment period closed on October 
6, 2016. FDA reviewed and considered all public comments received and 
revised the guidance as appropriate.

II. Significance of Guidance

    This guidance is being issued consistent with FDA's good guidance 
practices regulation (21 CFR 10.115). The guidance represents the 
current thinking of FDA on the ``Use of Public Human Genetic Variant 
Databases to Support Clinical Validity for Genetic and Genomic-Based In 
Vitro Diagnostics.'' It does not establish any rights for any person 
and is not binding on FDA or the public. You can use an alternative 
approach if it satisfies the requirements of the applicable statutes 
and regulations. This guidance is not subject to Executive Order 12866.

III. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by 
downloading an electronic copy from the internet. A search capability 
for all Center for Devices and Radiological Health guidance documents 
is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. This 
guidance document is also available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm or https://www.regulations.gov. Persons unable to download 
an electronic copy of ``Use of Public Human Genetic Variant Databases 
to Support Clinical Validity for Genetic and Genomic-Based In Vitro 
Diagnostics; Guidance for Stakeholders and Food and Drug Administration 
Staff'' may send an email request to [email protected] to 
receive an electronic copy of the document. Please use the document 
number 16008 to identify the guidance you are requesting.

IV. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of 
information. These collections of information are subject to review by 
the Office of Management and Budget (OMB) under the Paperwork Reduction 
Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 
the guidance document ``Use of Public Human Genetic Variant Databases 
to Support Clinical Validity for Genetic and Genomic-Based In Vitro 
Diagnostics; Guidance for Stakeholders and Food and Drug Administration 
Staff'' have been approved under OMB control number 0910-0850. The 
collections of information in the guidance document ``Requests for 
Feedback on Medical Device Submissions: The Pre-Submission Program and 
Meetings with Food and Drug Administration Staff; Guidance for Industry 
and Food and Drug Administration Staff'' have been approved under OMB 
control number 0910-0756. The collections of information regarding 
premarket submissions have been approved as follows: The collections of 
information in 21 CFR part 807, subpart E, have been approved under OMB 
control number

[[Page 16112]]

0910-0120 and the collections of information in 21 CFR part 814, 
subparts A through E, have been approved under OMB control number 0910-
0231.

    Dated: April 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-07686 Filed 4-12-18; 8:45 am]
 BILLING CODE 4164-01-P

16112 Federal Register / Vol. 83, No. 72 / Friday, April 13, 2018 / Notices

0910–0120 and the collections of DEPARTMENT OF HEALTH AND notify the Contact Person listed below
information in 21 CFR part 814, HUMAN SERVICES in advance of the meeting. The open
subparts A through E, have been session will be videocast and can be
approved under OMB control number National Institutes of Health accessed from the NIH Videocasting and
0910–0231. Podcasting website (http://videocast.
National Institute on Minority Health nih.gov).
Dated: April 9, 2018. and Health Disparities; Notice of A portion of the meeting will be
Leslie Kux, Closed Meeting closed to the public in accordance with
Associate Commissioner for Policy.
Pursuant to section 10(d) of the the provisions set forth in sections
[FR Doc. 2018–07686 Filed 4–12–18; 8:45 am] 552b(c)(4), and 552b(c)(6), Title 5
Federal Advisory Committee Act, as
BILLING CODE 4164–01–P
amended, notice is hereby given of the U.S.C., as amended. The grant
following meeting. applications and the discussions could
The meeting will be closed to the disclose confidential trade secrets or
DEPARTMENT OF HEALTH AND commercial property such as patentable
HUMAN SERVICES public in accordance with the
provisions set forth in sections material, and personal information
National Institutes of Health 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., concerning individuals associated with
as amended. The grant applications and the grant applications, the disclosure of
National Center for Advancing the discussions could disclose which would constitute a clearly
Translational Sciences; Notice of confidential trade secrets or commercial unwarranted invasion of personal
Closed Meeting property such as patentable materials, privacy.
and personal information concerning Name of Committee: Council of Councils.
Pursuant to section 10(d) of the individuals associated with the grant Open: May 18, 2018.
Federal Advisory Committee Act, as applications, the disclosure of which Time: 8:15 a.m. to 11:30 a.m.
amended, notice is hereby given of the would constitute a clearly unwarranted Agenda: Call to Order and Introductions;
following meeting. invasion of personal privacy. Announcements and Updates; Evaluating the
‘‘Broadening Experiences in Scientific
The meeting will be closed to the Name of Committee: National Institute on Training (BEST)’’ Awards; NIDA Update;
public in accordance with the Minority Health and Health Disparities Introduction to the Use of Non-Human
provisions set forth in sections Special Emphasis Panel; Prevention and Primates (NHP) in Addiction Research; NHP
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Treatment Research to Address HIV/AIDS Models of Drug Addiction.
as amended. The grant applications and Disparities in Woman in the U.S. Place: National Institutes of Health, 9000
the discussions could disclose Date: May 24, 2018. Rockville Pike, Building 31, C Wing, 6th
confidential trade secrets or commercial Time: 12:30 p.m. to 5:30 p.m. Floor, Conference Room 10, Bethesda, MD
property such as patentable material, Agenda: To review and evaluate grant 20892.
applications. Closed: May 18, 2018.
and personal information concerning Place: Gateway Building, 7201 Wisconsin
individuals associated with the grant Time: 12:30 p.m. to 2:30 p.m.
Ave., Suite 533, Bethesda, MD 20814 Agenda: Review of Grant Applications.
applications, the disclosure of which (Telephone Conference Call). Place: National Institutes of Health, 9000
would constitute a clearly unwarranted Contact Person: Maryline Laude-Sharp, Rockville Pike, Building 31, C Wing, 6th
invasion of personal privacy. Ph.D., Scientific Review Officer, National Floor, Conference Room 10, Bethesda, MD
Name of Committee: National Center for Institute on Minority Health and Health 20892.
Advancing Translational Sciences Special Disparities, National Institutes of Health, Open: May 18, 2018.
Emphasis Panel; New Therapeutic Uses. 7201 Wisconsin Ave., Bethesda, MD 20814, Time: 2:30 p.m. to 4:05 p.m.
Date: June 6, 2018. (301) 451–9536, mlaudesharp@nih.gov. Agenda: Division of Program Coordination,
Time: 8:00 a.m. to 5:00 p.m. Dated: April 10, 2018. Planning, and Strategic Initiatives (DPCPSI)
Agenda: To review and evaluate grant David D. Clary, Program Presentations; Update from the
applications. Office of Portfolio Analysis; Closing Remarks.
Program Analyst, Office of Federal Advisory Place: National Institutes of Health, 9000
Place: National Institutes of Health, One
Committee Policy. Rockville Pike, Building 31, C Wing, 6th
Democracy Plaza, Room 1066, 6701
Democracy Boulevard, Bethesda, MD 20892 [FR Doc. 2018–07755 Filed 4–12–18; 8:45 am] Floor, Conference Room 10, Bethesda, MD
(Virtual Meeting). BILLING CODE 4140–01–P 20892.
Contact Person: Barbara J. Nelson, Ph.D., Contact Person: Franziska Grieder, D.V.M.,
Scientific Review Officer, Office of Scientific Ph.D., Executive Secretary, Director, Office of
Review, National Center for Advancing DEPARTMENT OF HEALTH AND Research Infrastructure Programs, Division of
Translational Sciences (NCATS), National HUMAN SERVICES Program Coordination, Planning, and
Institutes of Health 6701 Democracy Blvd., Strategic Initiatives, Office of the Director,
Democracy 1, Room 1080, Bethesda, MD National Institutes of Health NIH, 6701 Democracy Boulevard, Room 948,
20892–4874, 301–435–0806, nelsonbj@ Bethesda, MD 20892, GriederF@mail.nih.gov,
mail.nih.gov. Office of the Director, National 301–435–0744.
(Catalogue of Federal Domestic Assistance Institutes of Health; Notice of Meeting Any interested person may file written
Program Nos. 93.859, Pharmacology, comments with the committee by forwarding
Physiology, and Biological Chemistry Pursuant to section 10(d) of the the statement to the Contact Person listed on
Research; 93.350, B–Cooperative Agreements; Federal Advisory Committee Act, as this notice. The statement should include the
93.859, Biomedical Research and Research amended, notice is hereby given of the name, address, telephone number and when
Training, National Institutes of Health, HHS) meeting of the Council of Councils. applicable, the business or professional
daltland on DSKBBV9HB2PROD with NOTICES

The meeting will be open to the affiliation of the interested person.
Dated: April 10, 2018. In the interest of security, NIH has
public as indicated below, with
David D. Clary, instituted stringent procedures for entrance
attendance limited to space available. onto the NIH campus. All visitor vehicles,
Program Analyst, Office of Federal Advisory Individuals who plan to attend and including taxicabs, hotel, and airport shuttles
Committee Policy. need special assistance, such as sign will be inspected before being allowed on
[FR Doc. 2018–07753 Filed 4–12–18; 8:45 am] language interpretation or other campus. Visitors will be asked to show one
BILLING CODE 4140–01–P reasonable accommodations, should form of identification (for example, a

VerDate Sep<11>2014 17:41 Apr 12, 2018 Jkt 244001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\13APN1.SGM 13APN1

Document Created: 2018-04-13 00:18:18
Document Modified: 2018-04-13 00:18:18

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice of availability.
Dates		The announcement of the guidance is published in the Federal Register on April 13, 2018.
Contact		Laura Koontz, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4553, Silver Spring, MD 20993-0002, 301-796-7561, [email protected]; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240- 402-7911.
FR Citation		83 FR 16110

83 FR 16110 - Use of Public Human Genetic Variant Databases To Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics; Guidance for Stakeholders and Food and Drug Administration Staff; Availability

DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration

Federal Register Volume 83, Issue 72 (April 13, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration